Prucalopride (DB06480): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Prucalopride is a first-in-class, small molecule drug representing a significant advancement in the management of chronic idiopathic constipation (CIC). As a highly selective, high-affinity serotonin-4 (5−HT4​) receptor agonist, its primary mechanism involves the stimulation of colonic peristalsis and the enhancement of gastrointestinal motility. This targeted action directly addresses the impaired motility that characterizes CIC. The development of prucalopride was distinguished by a rational drug design approach that successfully engineered a novel dihydrobenzofurancarboxamide chemical structure. This structure confers a high degree of selectivity for the 5−HT4​ receptor, thereby avoiding the off-target interactions with cardiac ion channels (e.g., hERG) that led to the withdrawal of earlier, less selective agents in this class. Consequently, prucalopride possesses a markedly improved cardiovascular safety profile, a critical feature that facilitated its global regulatory approvals.

Extensive clinical evaluation through numerous Phase III, randomized, placebo-controlled trials has consistently demonstrated the efficacy of prucalopride in normalizing bowel function and improving constipation-related symptoms in adults with CIC, particularly in those who have had an inadequate response to conventional laxative therapies. The drug is generally well-tolerated, with the most common adverse effects—headache and gastrointestinal symptoms—being transient and typically limited to the initial days of treatment. Its pharmacokinetic profile is favorable, characterized by high oral bioavailability, minimal metabolism, and a low potential for drug-drug interactions. Following its initial approval in Europe in 2009, prucalopride has been approved in numerous jurisdictions worldwide, including Canada and the United States, establishing it as a key therapeutic option. Furthermore, emerging research into its effects on central nervous system 5−HT4​ receptors has revealed potential pro-cognitive effects, opening novel avenues for future investigation beyond gastroenterology.

Drug Identification and Physicochemical Properties

A precise and unambiguous identification of a pharmaceutical agent is fundamental to its study and clinical application. This section provides a comprehensive summary of the nomenclature, chemical structure, and physicochemical properties of prucalopride.

Nomenclature and Identifiers

Prucalopride is known by a variety of names and codes across research, regulatory, and commercial contexts. It is most commonly available for clinical use as its succinate salt, prucalopride succinate.[1]

• Generic Name: Prucalopride [3]
• Brand Names: The drug is marketed globally under several brand names, most prominently Motegrity in the United States, Resolor in the European Union and other regions, and Resotran in Canada.[3] A more detailed list of international brand names is provided in the regulatory section of this report.
• Synonyms and Research Codes: During its development, prucalopride was referred to by research codes including R-093877, R093877, R-108512, and CS-219.[3]
• Database Identifiers: For cross-referencing in scientific and regulatory databases, prucalopride is assigned numerous unique identifiers, which are consolidated in Table 1.[3]

Chemical Structure and Class

Prucalopride's chemical structure is the basis for its unique pharmacological profile, particularly its high receptor selectivity.

• Systematic (IUPAC) Name: 4-Amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide.[4]
• Chemical Class: Prucalopride is a dihydrobenzofurancarboxamide derivative, belonging to the benzofuran family of compounds.[3] It is also classified as a member of the benzamides.[6] This structural classification is significant, as it distinguishes prucalopride from earlier serotonergic prokinetic agents such as cisapride (a substituted benzamide) and tegaserod (an aminoguanidine indole derivative).[7] This novel chemical backbone is directly responsible for its highly specific binding profile and improved safety.

Physical and Chemical Characteristics

The physical and chemical properties of prucalopride are relevant for its formulation, storage, and handling. These properties are summarized in Table 1. Prucalopride is typically formulated as a solid oral dosage form. It is described as a white to light yellow or light orange powder or crystal.[9] For stability, it is recommended to be stored under refrigerated conditions (0-10°C) and protected from air and heat, as it is noted to be sensitive to these conditions.[9]

Table 1: Key Identifiers and Physicochemical Properties of Prucalopride

Property	Value	Source(s)
Generic Name	Prucalopride	3
CAS Number	179474-81-8	4
DrugBank ID	DB06480	3
IUPAC Name	4-Amino-5-chloro-N-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide	4
Molecular Formula	C18​H26​ClN3​O3​	3
Average Molecular Weight	367.87 g/mol	3
Chemical Class	Dihydrobenzofurancarboxamide	3
Appearance	White to light yellow/orange powder or crystal	9
Solubility	DMSO: 20 mg/mL; The succinate salt is freely soluble in water.	1

Pharmacology and Mechanism of Action

The clinical utility and favorable safety profile of prucalopride are direct consequences of its highly specific pharmacological action. It represents a successful example of rational drug design aimed at maximizing therapeutic effect while minimizing off-target adverse events.

Primary Mechanism: Selective 5-HT4 Receptor Agonism

Prucalopride's primary mechanism of action is as a potent, selective, and high-affinity agonist of the serotonin type 4 (5−HT4​) receptor.[3] This receptor is a G-protein coupled receptor widely expressed in the gastrointestinal tract, particularly on enteric neurons, where it plays a crucial role in modulating motility and secretion.[7]

Prucalopride demonstrates high affinity for both known human 5−HT4​ receptor isoforms, 5-HT4a and 5-HT4b, with reported pKi values of 8.60 and 8.10, respectively.[6] The defining characteristic of its pharmacology is its exceptional selectivity. Its affinity for the

5−HT4​ receptor is more than 150-fold greater than its affinity for a large panel of over 50 other receptors, including other serotonin subtypes, dopamine receptors, and adrenergic receptors.[4] Some in vitro studies report a selectivity of over 290-fold.[6] Measurable binding to other receptors, such as the human dopamine D4 and sigma-1 (

σ1​) receptors, is only observed at supratherapeutic concentrations that are not clinically relevant.[6]

Pharmacodynamic Effects on Gastrointestinal Motility

The agonistic action of prucalopride at the 5−HT4​ receptor translates into potent enterokinetic (prokinetic) effects throughout the gastrointestinal tract.[3]

Upon binding to presynaptic 5−HT4​ receptors on cholinergic enteric neurons, prucalopride facilitates the release of the neurotransmitter acetylcholine.[6] This enhanced cholinergic activity stimulates the contraction of the longitudinal smooth muscle layer of the colon while simultaneously promoting the relaxation of the circular muscle layer.[3] This coordinated neuromuscular action is highly efficient at propelling luminal contents forward and is a key mechanism for its laxative effect.

A critical pharmacodynamic effect of prucalopride is its ability to stimulate and amplify high-amplitude propagating contractions (HAPCs), also known as giant migrating contractions or colonic mass movements.[3] These powerful, coordinated contractions are the primary propulsive force that initiates the urge to defecate. By directly promoting these movements, prucalopride addresses the fundamental pathophysiological deficit of impaired motility in patients with CIC.[16] While its primary clinical application is for colonic dysfunction, studies have shown that prucalopride also accelerates gastric emptying and small bowel transit, indicating a broader prokinetic effect on the upper gastrointestinal tract.[3]

The Basis for an Improved Cardiovascular Safety Profile

The development of prucalopride can be seen as a pharmacological success story, effectively reviving the 5−HT4​ agonist class after previous agents were withdrawn due to safety concerns. The failures of cisapride and tegaserod were linked to their lack of receptor selectivity, which resulted in significant off-target effects. Cisapride, for instance, exhibited affinity for the human ether-a-go-go-related gene (hERG) potassium channel, leading to QT interval prolongation and a risk of fatal cardiac arrhythmias.[4]

Prucalopride's novel dihydrobenzofurancarboxamide structure was specifically designed to confer high selectivity for the 5−HT4​ receptor. This molecular design was successful; at therapeutic concentrations, prucalopride has no meaningful interaction with the hERG K+ channel or other receptors implicated in cardiovascular adverse events, such as the 5−HT1B/D​ receptors.[3] This molecular-level safety has been confirmed in clinical settings. A dedicated thorough QT study found no clinically important QT interval prolongation, even at doses up to 10 mg (5 times the recommended dose).[18] Furthermore, pooled analyses of clinical trial data and a large, retrospective, observational cohort study found no increased risk of major adverse cardiovascular events (MACE)—defined as cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in patients treated with prucalopride compared to placebo or polyethylene glycol.[18] This robust cardiovascular safety profile was a pivotal factor in its successful regulatory approvals worldwide and is its most important distinguishing feature from its predecessors.

Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of prucalopride is characterized by high bioavailability, extensive distribution, minimal metabolism, and predictable renal elimination. These properties contribute to its reliable clinical performance and favorable drug-drug interaction profile.

Absorption and Bioavailability

Following oral administration, prucalopride is rapidly and well absorbed from the gastrointestinal tract. Peak plasma concentrations (Cmax​) are typically achieved within 2 to 3 hours post-dose.[4] The drug exhibits excellent absolute oral bioavailability, which is greater than 90%.[1] A key clinical advantage is the absence of a food effect; co-administration with food, including high-fat meals, does not significantly alter the rate or extent of absorption.[1] This allows for flexible dosing without regard to meals.

Distribution

Once absorbed, prucalopride is extensively distributed throughout the body tissues. This is evidenced by its large steady-state volume of distribution (Vdss​), reported to be between 567 L and 623 L.[3] Plasma protein binding is low at approximately 30%, meaning a large fraction of the drug exists in its unbound, pharmacologically active form in the circulation.[3] Studies have also shown a mean blood-to-plasma concentration ratio of 1.9, indicating that prucalopride is taken up into blood cells.[22]

Metabolism and Biotransformation

Prucalopride undergoes very limited metabolism in the body, which is a significant factor in its low potential for drug-drug interactions. In vitro studies using human liver microsomes have shown that metabolism is a very slow and minor pathway.[4] It does not inhibit the major cytochrome P450 (CYP450) enzymes at clinically relevant concentrations and is considered only a weak substrate for CYP3A4 in vitro.[3]

The vast majority of the administered dose is excreted as the unchanged parent drug.[4] While seven minor metabolites have been identified in urine and feces, they represent a very small fraction of the total dose. The most abundant of these, an O-desmethylated acid metabolite known as R107504, accounts for only about 3% of the dose in excreta and less than 2% of the total plasma exposure.[16]

Elimination and Half-Life

The primary route of elimination for prucalopride is renal excretion of the unchanged drug.[4] The average plasma clearance is approximately 317 mL/min.[4] This rate of renal clearance exceeds the typical glomerular filtration rate, which strongly indicates that elimination occurs via both passive glomerular filtration and active tubular secretion.[3] Prucalopride has been identified as a weak substrate for the P-glycoprotein (P-gp) efflux transporter, which may contribute to its active secretion in the renal tubules.[10]

Mass balance studies using radiolabeled prucalopride have demonstrated near-complete recovery of the administered dose over a 10-day period, with a mean of 84.2% recovered in urine and 13.3% in feces.[16] The terminal elimination half-life of prucalopride is approximately 24 hours, or one day.[4] This pharmacokinetic property supports a convenient once-daily dosing regimen. Following initiation of once-daily dosing, steady-state plasma concentrations are achieved within 3 to 4 days.[4]

Clinical Evidence and Therapeutic Efficacy

The clinical utility of prucalopride for the treatment of chronic idiopathic constipation is supported by a robust program of clinical trials, including multiple pivotal Phase III studies, long-term extension studies, and meta-analyses.

Approved Indication: Chronic Idiopathic Constipation (CIC)

Prucalopride is indicated for the symptomatic treatment of CIC in adults.[3] CIC is a prevalent functional gastrointestinal disorder defined by persistent, difficult, or infrequent bowel movements in the absence of an identifiable organic cause.[8] Diagnosis is typically based on the Rome criteria, which include experiencing at least two of the following symptoms for a sustained period: straining during more than 25% of defecations, lumpy or hard stools in more than 25% of defecations, a sensation of incomplete evacuation for more than 25% of defecations, a sensation of anorectal obstruction, the use of manual maneuvers to facilitate defecation, and having fewer than three spontaneous bowel movements per week.[3]

Prucalopride is positioned as a second-line therapy, recommended for patients who have failed to achieve adequate relief with at least two different classes of conventional laxatives (e.g., osmotic and stimulant laxatives) at optimal doses.[1]

Analysis of Pivotal Clinical Trials

The efficacy of prucalopride was established in three pivotal, identically designed, 12-week, multicenter, randomized, double-blind, placebo-controlled Phase III trials (NCT00483886, NCT00488137, and NCT00485940).[26] These studies, along with others, formed the basis of its regulatory approvals.

The consistent primary efficacy endpoint across these pivotal trials was the proportion of patients achieving a weekly average of three or more spontaneous complete bowel movements (SCBMs) over the 12-week treatment period.[28] An SCBM is defined as a bowel movement that occurs without the aid of laxatives and is associated with a sensation of complete evacuation.

The results from these trials consistently demonstrated the superiority of prucalopride over placebo. As shown in Table 2, an integrated analysis of these trials, as well as individual trial reports, showed that a significantly higher percentage of patients treated with prucalopride 2 mg achieved the primary endpoint compared to those receiving placebo.[28] For example, in the study by Camilleri et al. (NCT00483886), 30.9% of patients in the 2 mg prucalopride group were responders, compared to only 12.0% in the placebo group (

p<0.001).[30] A 2016 meta-analysis of sixteen randomized controlled trials involving 3,943 patients further confirmed the clinical benefit of both 1 mg and 2 mg doses of prucalopride in increasing the frequency of spontaneous bowel movements.[31]

In addition to the primary endpoint, prucalopride also showed statistically significant improvements in a range of secondary endpoints, including the proportion of patients with an average increase of one or more SCBMs per week from baseline, improvements in stool consistency as measured by the Bristol Stool Form Scale, and reductions in the severity of straining.[30]

Table 2: Summary of Efficacy Outcomes from Pivotal Phase III CIC Trials

Trial Identifier	Patient Population (N)	Treatment Duration	Prucalopride Dose	Primary Endpoint (% of patients with ≥3 SCBMs/week)	Prucalopride Result (%)	Placebo Result (%)	Statistical Significance (p-value)	Source(s)
NCT00483886	620	12 weeks	2 mg	Average ≥3 SCBMs/week	30.9	12.0	<0.001	30
NCT00488137	713	12 weeks	2 mg	Average ≥3 SCBMs/week	23.6	11.3	<0.001	26
NCT00485940	641	12 weeks	2 mg	Average ≥3 SCBMs/week	24.7	9.2	<0.001	26
Integrated Analysis (3 trials)	1974	12 weeks	2 mg	Average ≥3 SCBMs/week	27.8	10.4	<0.001	28

Long-Term Efficacy and Patient-Reported Outcomes

The benefits of prucalopride extend beyond short-term bowel function normalization. Open-label extension studies, where patients continued treatment for up to 24 months, demonstrated that the efficacy and improvement in bowel habits were sustained over the long term.[4]

Crucially, treatment with prucalopride also leads to significant improvements in patients' health-related quality of life (HRQoL) and satisfaction with treatment. These patient-reported outcomes were assessed using validated instruments such as the Patient Assessment of Constipation Quality of Life (PAC-QOL) questionnaire and the Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire.[7] An integrated analysis of the pivotal trials revealed that improvements in PAC-QOL scores were strongly correlated with improvements in constipation symptoms. After 12 weeks, a clinically meaningful improvement in the PAC-QOL overall score was seen in 36.5% of prucalopride-treated patients compared to just 18.5% of those on placebo (

p<0.001).[26]

A Critical Review of Conflicting Evidence (The NCT01424228 Trial)

While the body of evidence for prucalopride's 12-week efficacy is robust and consistent, one long-term, 24-week, Phase IV randomized controlled trial (NCT01424228) yielded a different result.[34] In this study, prucalopride did not demonstrate a statistically significant improvement over placebo for the primary endpoint of achieving ≥3 SCBMs/week (25.1% for prucalopride vs. 20.7% for placebo;

p=0.367).[35]

This null finding stands in contrast to the multiple positive 12-week trials and long-term open-label data. The investigators of the trial were unable to identify a definitive cause for this discrepancy.[35] However, a critical analysis suggests that a significant factor may have been an unusually high and sustained placebo response rate (20.7%) over the extended 24-week duration. This rate is nearly double the placebo response rate of approximately 10-12% observed consistently across the shorter 12-week pivotal trials.[30] This phenomenon highlights a well-known methodological challenge in clinical trials for functional and symptom-based disorders, where the placebo effect can be substantial and can increase over longer study periods. The response rate in the prucalopride arm (25.1%) was comparable to that seen in the positive 12-week studies, suggesting that the trial's failure to meet its endpoint was driven by the inflated placebo response rather than a lack of drug effect. Therefore, the totality of evidence, which includes multiple positive short-term RCTs and supportive long-term open-label data, provides a more complete picture of prucalopride's clinical value than this single anomalous result.

Safety Profile and Tolerability

Prucalopride is generally well-tolerated, with a safety profile that has been extensively characterized in clinical trials involving thousands of patients and confirmed through post-marketing surveillance.

Common and Transient Adverse Events

The most frequently reported adverse events associated with prucalopride are headache and gastrointestinal symptoms, including abdominal pain, nausea, and diarrhea.[4] These events occur in ≥2% of patients treated with prucalopride and at a rate higher than placebo.[21] A key characteristic of these side effects is their temporal profile; they predominantly occur at the beginning of treatment, often on the first day, and are typically mild to moderate in intensity and transient, usually resolving within a few days as the body adapts to the medication.[4]

Other less common adverse reactions, reported in less than 2% of patients, include dizziness, fatigue, vomiting, flatulence, decreased appetite, abnormal gastrointestinal sounds, migraine, and pollakiuria (abnormally frequent urination).[16]

Warnings, Precautions, and Serious Adverse Events

Regulatory agencies have highlighted specific warnings and precautions for the use of prucalopride.

• Suicidal Ideation and Behavior: In clinical trials, rare instances of suicide, suicide attempts, and suicidal ideation were reported in patients treated with prucalopride.[18] Although a causal relationship between prucalopride and an increased risk of these events has not been established, the U.S. FDA prescribing information includes a warning to monitor all patients for persistent worsening of depression or the emergence of suicidal thoughts and behaviors. Patients and their caregivers are instructed to be alert for unusual changes in mood or behavior and to discontinue the medication immediately and contact a healthcare provider if such symptoms occur.[19]
• Hypersensitivity Reactions: Post-marketing surveillance has identified rare cases of hypersensitivity reactions, including dyspnea, rash, pruritus, urticaria, and facial edema.[18] A history of hypersensitivity to prucalopride or any of its excipients is a contraindication to its use.
• Cardiovascular Safety: As detailed previously, the cardiovascular safety of prucalopride is a key feature. Extensive clinical data have not shown an increased risk of major adverse cardiovascular events (MACE) or other significant cardiovascular effects, such as QT interval prolongation.[18]

Contraindications

The use of prucalopride is strictly contraindicated in certain patient populations where its prokinetic effects could be harmful [4]:

• Patients with a known hypersensitivity to prucalopride or any of its components.
• Patients with intestinal perforation or obstruction due to a structural or functional disorder of the gut wall.
• Patients with obstructive ileus.
• Patients with severe inflammatory conditions of the intestinal tract, such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum.
• Patients with renal impairment severe enough to require dialysis.

Use in Specific Populations

Dosage adjustments and specific considerations are necessary for certain patient populations.

• Renal Impairment: Prucalopride is primarily eliminated by the kidneys. In patients with severe renal impairment (creatinine clearance [CrCl] <30 mL/min), systemic exposure to the drug is increased. Therefore, the dose should be reduced to 1 mg once daily in this population. The drug should be avoided or is contraindicated in patients with end-stage renal disease requiring dialysis.[14] No dose adjustment is necessary for mild to moderate renal impairment.
• Hepatic Impairment: For patients with severe hepatic impairment (Child-Pugh Class C), a reduced starting dose of 1 mg once daily is recommended, which may be increased to 2 mg if tolerated and required for efficacy. No dose adjustment is needed for patients with mild or moderate hepatic impairment.[18]
• Geriatric Patients: In individuals older than 65 years, a starting dose of 1 mg once daily is often recommended, with titration to 2 mg once daily if needed. This cautious approach is primarily due to the higher likelihood of age-related decline in renal function in this population.[5]
• Pregnancy and Lactation: There are insufficient data from human studies to establish the safety of prucalopride during pregnancy. Animal reproduction studies have not shown adverse developmental effects.[16] A pregnancy exposure registry has been established to monitor outcomes in women exposed to the drug during pregnancy.[16] Prucalopride is known to be excreted in human breast milk. The decision to use the drug during lactation requires careful consideration of the potential benefits for the mother against any potential risks to the breastfed infant.[14]

Dosage, Administration, and Drug Interactions

Proper dosing and administration are crucial for optimizing the efficacy and safety of prucalopride. Its favorable pharmacokinetic profile results in a relatively low potential for clinically significant drug-drug interactions.

Recommended Dosing Regimens

The recommended dosing for prucalopride is straightforward, reflecting its long half-life and lack of food effect.

• Standard Adult Dose for CIC: The standard and maximum recommended dose for adults is 2 mg taken orally once daily.[14] Clinical trials have shown that doses higher than 2 mg (e.g., 4 mg) do not provide additional clinical benefit and are not recommended.[14]
• Administration: The tablet can be administered at any time of day, with or without food, offering convenience and flexibility for patients.[14]
• Dose Adjustments in Special Populations: As detailed in Table 3, dose adjustments are required for specific patient groups to account for altered pharmacokinetics or increased sensitivity.[14]

Table 3: Recommended Dosing Adjustments in Special Populations

Patient Population	Recommended Dose / Action	Source(s)
Severe Renal Impairment (CrCl < 30 mL/min)	1 mg once daily	16
End-Stage Renal Disease (requiring dialysis)	Contraindicated / Avoid use	18
Severe Hepatic Impairment (Child-Pugh Class C)	Start with 1 mg once daily; may increase to 2 mg if tolerated	18
Geriatric Patients (>65 years)	Start with 1 mg once daily; may increase to 2 mg if needed	18

Potential for Drug-Drug Interactions

One of the significant advantages of prucalopride is its low potential for pharmacokinetic drug-drug interactions. This stems directly from its minimal reliance on the CYP450 enzyme system for metabolism. While extensive databases may list numerous theoretical interactions based on shared physiological pathways, very few are considered clinically meaningful.

• Pharmacokinetic Interactions: Prucalopride does not inhibit major CYP450 enzymes or P-gp at clinically relevant concentrations.[3] It is a weak substrate for P-gp and CYP3A4. Co-administration with a potent inhibitor of both pathways, such as ketoconazole (200 mg twice daily), was found to increase prucalopride systemic exposure (AUC) by approximately 40%.[10] This magnitude of increase is not considered to be clinically relevant, and no dose adjustment is required. A 30% increase in the plasma concentration of erythromycin has been observed during co-treatment with prucalopride, though the mechanism is not fully understood and the clinical significance is likely low.[10]
• Pharmacodynamic Interactions: Drugs with anticholinergic properties may theoretically antagonize the prokinetic effects of prucalopride, which relies on facilitating acetylcholine release. Therefore, co-administration with such agents could potentially reduce its efficacy.[3]
• Oral Contraceptives: In cases where prucalopride induces severe diarrhea, the absorption and efficacy of oral contraceptives may be diminished. It is recommended that patients use an additional, non-hormonal method of contraception in such instances.[39]

Regulatory Status and Global Market Landscape

Prucalopride has undergone extensive regulatory review and is now an established therapy for CIC in many parts of the world. Its approval journey reflects the high bar for safety set after the withdrawal of earlier serotonergic agents.

Global Regulatory Approval History

The regulatory timeline for prucalopride began in Europe and progressively expanded globally over nearly a decade.

• European Union (EMA): Prucalopride was first approved by the EMA on October 15, 2009, under the brand name Resolor.[3] The initial indication was for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. This indication was later expanded to include all adults.[10]
• Canada (Health Canada): Approval was granted on December 7, 2011, for the brand Resotran.[3]
• United States (FDA): After a comprehensive review of its efficacy and, critically, its cardiovascular safety data, the U.S. FDA approved prucalopride on December 17, 2018, under the brand name Motegrity.[3] The New Drug Application (NDA 210166) had been accepted for review earlier that year on March 5, 2018.[46]
• Other Regions: The drug has also secured approval in numerous other countries, including Australia (as Resotrans), Switzerland (2010), Israel (2014), China (2014), Japan, and several nations in Asia and South America.[1]
• Generic Availability: In the United States, the first generic versions of prucalopride tablets received FDA approval and began to launch around January 2025, increasing market competition and access.[28]

International Brand Names and Availability

Prucalopride is marketed under various brand names depending on the region.

• Primary International Brands: The most common global brands are Motegrity (U.S.), Resolor (Europe, Asia, parts of South America), and Resotran (Canada).[2] The brand name Resotrans is used in Australia, New Zealand, and Mexico.[1]
• Regional Brands: A number of local brand names exist, particularly in South America. In Argentina, available brands include Prucal, Prulide, Pruxal, Ercanol, and Prucacinet.[51] In Chile, brands include Pruval and Prucalex.[2]
• Market Position: Market analyses indicate that North America and Europe represent the largest markets for prucalopride, driven by high prevalence of CIC and established reimbursement systems. The Asia-Pacific region, including China and Japan, is also a significant and growing market.[58]

Broader Therapeutic Context and Future Directions

Prucalopride occupies a distinct position in the therapeutic armamentarium for CIC. Understanding its comparative profile and exploring its potential beyond its primary indication are key to appreciating its full clinical and scientific value.

Comparative Analysis with Other CIC Agents

The treatment landscape for CIC has evolved to include several classes of prescription medications. Prucalopride's primary competitors are the secretagogues, lubiprostone and linaclotide, which have fundamentally different mechanisms of action. A comparative profile is presented in Table 4.

While prucalopride is a prokinetic agent that directly stimulates colonic motility and HAPCs, the secretagogues work by increasing intestinal fluid secretion.[13] Lubiprostone (Amitiza) is a chloride channel activator, and linaclotide (Linzess) is a guanylate cyclase-C agonist; both mechanisms lead to an influx of chloride and water into the intestinal lumen, which softens stool and facilitates its passage.[31]

Meta-analyses and network meta-analyses suggest that all three agents are superior to placebo for treating CIC.[62] Direct head-to-head trials are lacking, but indirect comparisons suggest broadly comparable efficacy. The Number Needed to Treat (NNT) to see one additional patient respond is approximately 4 for lubiprostone and 6 for both prucalopride and linaclotide.[63] One network meta-analysis that focused on patients who had previously failed laxatives ranked prucalopride first for efficacy over a 12-week period.[64] The choice of agent is often guided by the patient's specific symptom profile and the distinct adverse effect profiles of the drugs. Prucalopride is primarily associated with headache, while lubiprostone is known for causing nausea, and linaclotide's most common side effect is diarrhea.[63]

Table 4: Comparative Profile of Modern Therapies for Chronic Idiopathic Constipation

Feature	Prucalopride (Motegrity)	Lubiprostone (Amitiza)	Linaclotide (Linzess)
Drug Class	Serotonin 5-HT4 Receptor Agonist	Chloride Channel Activator	Guanylate Cyclase-C Agonist
Mechanism of Action	Prokinetic: Stimulates colonic peristalsis and high-amplitude propagating contractions (HAPCs)	Secretagogue: Increases intestinal fluid secretion by activating ClC-2 channels	Secretagogue: Increases intestinal fluid secretion by activating the CFTR ion channel via cGMP
Standard Dosing (CIC)	2 mg once daily	24 mcg twice daily	145 mcg once daily
Efficacy (NNT vs. Placebo)	~6	~4	~6
Primary Adverse Effects	Headache, abdominal pain, nausea, diarrhea (often transient)	Nausea, diarrhea, headache	Diarrhea (most common), abdominal pain, flatulence
Source(s)	3	42	42

Investigational and Off-Label Applications

The prokinetic properties of prucalopride suggest its potential utility in other gastrointestinal motility disorders. Preliminary evidence and clinical interest exist for its off-label use in gastroparesis, postoperative ileus, and opioid-induced constipation (OIC).[13]

Perhaps the most novel and unexpected area of investigation for prucalopride lies outside the gastrointestinal system. The 5−HT4​ receptor is also expressed in the central nervous system, including in brain regions critical for learning and memory, such as the hippocampus.[4] Prucalopride has been shown to have good brain penetration.[70] This has led to studies investigating its potential cognitive-enhancing effects. Small clinical trials in healthy volunteers have demonstrated that administration of prucalopride can improve performance on memory recall tasks and is associated with increased neural activation in the hippocampus and functionally related brain areas.[4] This serendipitous finding is a compelling demonstration of the gut-brain axis and suggests that

5−HT4​ receptor agonism could be a future therapeutic strategy for cognitive impairments associated with depression or other neuropsychiatric conditions. This transforms the perception of prucalopride from a gut-specific agent to a potential tool for modulating central nervous system function.

Conclusion and Expert Insights

Prucalopride represents a landmark achievement in gastroenterological pharmacology. Its development and successful global registration effectively redeemed the 5−HT4​ receptor agonist class, which had been marred by the cardiovascular safety failures of its predecessors. This was accomplished through a deliberate and successful strategy of rational drug design, yielding a novel chemical entity with high selectivity for its target receptor, thereby designing out the off-target effects responsible for the previous toxicity.

The clinical profile of prucalopride is robust. Its efficacy in treating adults with chronic idiopathic constipation who are refractory to standard laxatives is well-established through a large body of high-quality clinical trial evidence. It consistently demonstrates superiority over placebo in normalizing bowel function, alleviating associated symptoms, and improving patient quality of life. Its pharmacokinetic properties are nearly ideal for a chronic-use medication, with high oral bioavailability, a lack of food effect, minimal metabolism, and a consequently low risk of drug-drug interactions, simplifying its clinical use.

While generally well-tolerated, with common side effects being transient, the prescribing information includes an important warning regarding the potential for suicidal ideation and behavior, necessitating careful patient selection and monitoring. Its staggered but widespread global regulatory approval underscores the medical community's confidence in its benefit-risk profile.

Looking forward, prucalopride's story continues to evolve. While its place in managing CIC is secure, the most scientifically intriguing developments are emerging from research into its central nervous system effects. The discovery of its pro-cognitive properties in early studies opens up an entirely new and unexpected therapeutic horizon. This finding not only suggests a potential new life for prucalopride or next-generation analogues in treating cognitive deficits but also serves as a powerful illustration of the intricate pharmacological connections of the gut-brain axis. In conclusion, prucalopride is not only a cornerstone therapy for a challenging functional bowel disorder but also a valuable scientific tool for exploring the broader physiological roles of the serotonergic system.

Works cited

1. Australian Public Assessment Report for Prucalopride - Therapeutic Goods Administration (TGA), accessed August 4, 2025, https://www.tga.gov.au/sites/default/files/auspar-resotrans.pdf
2. Prucalopride (International database) - Drugs.com, accessed August 4, 2025, https://www.drugs.com/international/prucalopride.html
3. Prucalopride: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB06480
4. Prucalopride - Wikipedia, accessed August 4, 2025, https://en.wikipedia.org/wiki/Prucalopride
5. Prucalopride (oral route) - Side effects & dosage - Mayo Clinic, accessed August 4, 2025, https://www.mayoclinic.org/drugs-supplements/prucalopride-oral-route/description/drg-20452343
6. Prucalopride | 179474-81-8 - ChemicalBook, accessed August 4, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB21179613.htm
7. Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3108672/
8. Prucalopride | C18H26ClN3O3 | CID 3052762 - PubChem, accessed August 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/3052762
9. Prucalopride - CAS RN: 179474-81-8 - TCI Chemicals, accessed August 4, 2025, https://www.tcichemicals.com/US/en/p/P2467
10. Resolor, INN-prucalopride, accessed August 4, 2025, https://ec.europa.eu/health/documents/community-register/2009/2009101566130/anx_66130_en.pdf
11. Prucalopride = 98 HPLC 179474-81-8 - Sigma-Aldrich, accessed August 4, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/sml1371
12. 179474-81-8|4-Amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl) - BLDpharm, accessed August 4, 2025, https://www.bldpharm.com/products/179474-81-8.html
13. What is the mechanism of action and uses of Prucalopride (Serotonin 5-HT4 receptor agonist)? - Dr.Oracle, accessed August 4, 2025, https://www.droracle.ai/articles/94092/prucalopride-its-mechanism-of-action-and-uses-
14. Resolor, INN-prucalopride - EMA, accessed August 4, 2025, https://www.ema.europa.eu/en/documents/product-information/resolor-epar-product-information_en.pdf
15. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation, accessed August 4, 2025, https://www.tandfonline.com/doi/pdf/10.1517/17425255.2012.719497
16. Motegrity (prucalopride) dosing, indications, interactions, adverse effects, and more, accessed August 4, 2025, https://reference.medscape.com/drug/motegrity-prucalopride-1000289
17. Safety/Efficacy of Prucalopride in Korean Patients with Chronic Constipation: Post-marketing Surveillance, accessed August 4, 2025, https://www.kjg.or.kr/journal/view.html?doi=10.4166/kjg.2021.099
18. Prucalopride Monograph for Professionals - Drugs.com, accessed August 4, 2025, https://www.drugs.com/monograph/prucalopride.html
19. FDA OKs Prucalopride (Motegrity) for Chronic Idiopathic Constipation - Medscape, accessed August 4, 2025, https://www.medscape.com/viewarticle/906732
20. Prucalopride 2 mg Film-coated Tablets - Summary of Product Characteristics (SmPC) - (emc) | 12623, accessed August 4, 2025, https://www.medicines.org.uk/emc/product/12623/smpc
21. MOTEGRITY (prucalopride) tablets, for oral use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210166s000lbl.pdf
22. A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/27614912/
23. Prucalopride (Motegrity) | Davis's Drug Guide - Nursing Central, accessed August 4, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109868/all/prucalopride?q=SAD
24. Prucalopride: MedlinePlus Drug Information, accessed August 4, 2025, https://medlineplus.gov/druginfo/meds/a619011.html
25. CP.PMN.194 Prucalopride (Motegrity) - Delaware First Health, accessed August 4, 2025, https://www.delawarefirsthealth.com/content/dam/centene/delaware/Policies/DrugPolicies/DrugPoliciesP/DE.PMN.194%20Prucalopride%20(Motegrity)%2001.23.pdf
26. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/25581251/
27. Cost-effectiveness of prucalopride in the treatment of chronic constipation in the Netherlands, accessed August 4, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2015.00067/full
28. Prucalopride Tablets for Chronic Idiopathic Constipation Launches, Approved for 180-Day CGT Designation - Pharmacy Times, accessed August 4, 2025, https://www.pharmacytimes.com/view/prucalopride-tablets-for-chronic-idiopathic-constipation-launches-approved-for-180-day-cgt-designation
29. Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT00483886
30. A placebo-controlled trial of prucalopride for severe chronic ..., accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/18509121/
31. Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials - Journal of Neurogastroenterology and Motility, accessed August 4, 2025, https://www.jnmjournal.org/journal/view.html?uid=1144&vmd=Full
32. Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6553670/
33. Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies - Journal of Neurogastroenterology and Motility, accessed August 4, 2025, https://www.jnmjournal.org/journal/view.html?uid=869&vmd=Full
34. Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged ≥ 18 Years | ClinicalTrials.gov, accessed August 4, 2025, https://clinicaltrials.gov/study/NCT01424228
35. A randomized, double-blind, placebo-controlled trial to evaluate the ..., accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/25808103/
36. (PDF) A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride - ResearchGate, accessed August 4, 2025, https://www.researchgate.net/publication/274091261_A_randomized_double-blind_placebo-controlled_trial_to_evaluate_the_efficacy_safety_and_tolerability_of_long-term_treatment_with_prucalopride
37. Prucalopride: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 4, 2025, https://www.rxlist.com/prucalopride/generic-drug.htm
38. 210166Orig1s000 - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000MultidisciplineR.pdf
39. ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - Resolor, INN-prucalopride, accessed August 4, 2025, https://ec.europa.eu/health/documents/community-register/2021/20210617152204/anx_152204_en.pdf
40. FDA Briefing Document Gastrointestinal Drug Advisory Committee Meeting October 18, 2018, accessed August 4, 2025, https://www.fda.gov/media/119036/download
41. Prucalopride Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 4, 2025, https://www.drugs.com/dosage/prucalopride.html
42. Linaclotide, lubiprostone and prucalopride interactions - The Pharmaceutical Journal, accessed August 4, 2025, https://pharmaceutical-journal.com/article/ld/linaclotide-lubiprostone-and-prucalopride-interactions
43. 210166Orig1s000 - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210166Orig1s000OtherR.pdf
44. Prucalopride succinate (Resolor) - New Drug Approvals, accessed August 4, 2025, https://newdrugapprovals.org/2016/07/27/prucalopride-succinate-resolor/
45. FDA approves Shire's Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC) - Takeda Pharmaceuticals, accessed August 4, 2025, https://www.takeda.com/newsroom/shire-news-releases/2018/qmmwqk/
46. U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation - Takeda Pharmaceuticals, accessed August 4, 2025, https://www.takeda.com/newsroom/shire-news-releases/2018/jo7p3e/
47. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3509366/
48. Lupin Receives Approval from U.S. FDA for Prucalopride Tablets, accessed August 4, 2025, https://www.lupin.com/lupin-receives-approval-from-u-s-fda-for-prucalopride-tablets/
49. Prucalopride Tablets for Chronic Idiopathic Constipation Launches, Approved for 180-Day CGT Designation - American Journal of Managed Care, accessed August 4, 2025, https://www.ajmc.com/view/prucalopride-tablets-for-chronic-idiopathic-constipation-launches-approved-for-180-day-cgt-designation
50. Prucalopride (as succinate) tablet film coated 1mg and 2mg - Medsafe, accessed August 4, 2025, https://www.medsafe.govt.nz/profs/datasheet/r/resotranstab.pdf
51. PRUCAL 1 X 30 CMP - Dr. Zeta, accessed August 4, 2025, https://www.drzeta.com.ar/prucal-1-x-30-cmp.html
52. Prulide - Baliarda, accessed August 4, 2025, https://www.baliarda.com.ar/Adjuntos/Productos/338/Prulide_Paciente.pdf
53. Info-Producto-Prucal.pdf, accessed August 4, 2025, http://www.actagastro.org/Descargables/Info-Producto-Prucal.pdf
54. Medida del prospecto cerrado - Laboratorio Ariston, accessed August 4, 2025, https://www.laboratorio-ariston.com.ar/prospecto/16690390703.pdf
55. Prucaloprida - Laboratorio Dominguez, accessed August 4, 2025, https://www.labdominguez.com.ar/composicin-activos/prucaloprida/
56. Active Ingredient: Prucalopride - SAVAL | Pharmaceuticals, accessed August 4, 2025, https://www.savalcorp.com/en/products/active-ingredient.html?c=9&pa=179
57. Pruval Prucaloprida 2mg 30 Comprimidos Recubiertos - Salcobrand, accessed August 4, 2025, https://salcobrand.cl/products/pruval-prucaloprida-2mg-30-comprimidos-recubiertos
58. Prucalopride Market size & future growth 2035 - WiseGuy Reports, accessed August 4, 2025, https://www.wiseguyreports.com/reports/prucalopride-market
59. Prucalopride Succinate Market Research Report 2033, accessed August 4, 2025, https://growthmarketreports.com/report/prucalopride-succinate-market
60. Global Prucalopride Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030 - Absolute Reports, accessed August 4, 2025, https://www.absolutereports.com/global-prucalopride-market-27905906
61. Therapeutic Class Overview - Irritable Bowel Syndrome and Constipation Agents - Medicaid.nv.gov, accessed August 4, 2025, https://www.medicaid.nv.gov/Downloads/provider/Irritable_Bowel_Syndrome_Agents_2019-0611.pdf
62. Novel therapies for constipation - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3857447/
63. Effect of laxatives and pharmacological therapies in chronic ... - NCBI, accessed August 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK81097/
64. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis - Mayo Clinic, accessed August 4, 2025, https://mayoclinic.elsevierpure.com/en/publications/efficacy-of-drugs-in-chronic-idiopathic-constipation-a-systematic
65. Linaclotide vs Lubiprostone Comparison - Drugs.com, accessed August 4, 2025, https://www.drugs.com/compare/linaclotide-vs-lubiprostone
66. Lubiprostone vs Prucalopride Comparison - Drugs.com, accessed August 4, 2025, https://www.drugs.com/compare/lubiprostone-vs-prucalopride
67. An update on prucalopride in the treatment of chronic constipation - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5673021/
68. Motegrity (prucalopride): Side effects, dosage, uses, and more - Medical News Today, accessed August 4, 2025, https://www.medicalnewstoday.com/articles/drugs-motegrity
69. Motegrity (prucalopride): Side Effects, Uses, Dosage & More - GoodRx, accessed August 4, 2025, https://www.goodrx.com/motegrity/what-is
70. Constipation Med Boosts Cognitive Performance in Mental Illness - Medscape, accessed August 4, 2025, https://www.medscape.com/viewarticle/960451